BACKGROUND: The present study was undertaken to test the hypothesis that women are more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients exposed to the QT-prolonging antiarrhythmic drug d,l-sotalol. METHODS AND RESULTS: In a database derived from 22 clinical trials involving 3135 adult patients who received oral d,l-sotalol (median follow-up, 164 days), TdP developed in 44 (1.9%) of 2336 men and in 33 (4.1%) of 799 women (P < .001). Logistic regression analysis identified female sex (P < .0001), presenting arrhythmia of sustained ventricular tachycardia or fibrillation (P < .0001), history of congestive heart failure (P < .001), and d,l-sotalol dose > 320 mg/d (P < .001) as factors most predictive of TdP; in addition to these, a serum creatinine > 1.4 mg/dL in women and > 1.6 mg/dL in men was weakly predictive (P < .05). After adjustment for these risk factors, women had threefold greater odds of developing TdP than men. The sex difference in TdP risk was age independent and could not be explained by differential dose-related bradycardic responses in women versus men. CONCLUSIONS: Women are at increased risk of developing TdP during-administration of d,l-sotalol. This finding needs to be taken into account, together with other TdP risk factors, when patients are treated with this antiarrhythmic agent. Given the consistency between the present and other recent observations, greater caution in women regarding use of QT-prolonging drugs, in general, is advisable.
BACKGROUND: The present study was undertaken to test the hypothesis that women are more prone than men to develop torsade de pointes (TdP) in a defined cohort of patients exposed to the QT-prolonging antiarrhythmic drug d,l-sotalol. METHODS AND RESULTS: In a database derived from 22 clinical trials involving 3135 adult patients who received oral d,l-sotalol (median follow-up, 164 days), TdP developed in 44 (1.9%) of 2336 men and in 33 (4.1%) of 799 women (P < .001). Logistic regression analysis identified female sex (P < .0001), presenting arrhythmia of sustained ventricular tachycardia or fibrillation (P < .0001), history of congestive heart failure (P < .001), and d,l-sotalol dose > 320 mg/d (P < .001) as factors most predictive of TdP; in addition to these, a serum creatinine > 1.4 mg/dL in women and > 1.6 mg/dL in men was weakly predictive (P < .05). After adjustment for these risk factors, women had threefold greater odds of developing TdP than men. The sex difference in TdP risk was age independent and could not be explained by differential dose-related bradycardic responses in women versus men. CONCLUSIONS:Women are at increased risk of developing TdP during-administration of d,l-sotalol. This finding needs to be taken into account, together with other TdP risk factors, when patients are treated with this antiarrhythmic agent. Given the consistency between the present and other recent observations, greater caution in women regarding use of QT-prolonging drugs, in general, is advisable.
Authors: Jonathan Buber; Jehu Mathew; Arthur J Moss; W Jackson Hall; Alon Barsheshet; Scott McNitt; Jennifer L Robinson; Wojciech Zareba; Michael J Ackerman; Elizabeth S Kaufman; David Luria; Michael Eldar; Jeffrey A Towbin; Michael Vincent; Ilan Goldenberg Journal: Circulation Date: 2011-05-31 Impact factor: 29.690
Authors: James E Tisdale; Heather A Jaynes; Brian R Overholser; Kevin M Sowinski; Mark D Fisch; Jo E Rodgers; Ahmed Aldemerdash; Chia-Chi Hsu; Nan Wang; Elena Tomaselli Muensterman; Vijay U Rao; Richard J Kovacs Journal: J Card Fail Date: 2020-06-24 Impact factor: 5.712
Authors: Lars Anneken; Stefan Baumann; Patrick Vigneault; Peter Biliczki; Corinna Friedrich; Ling Xiao; Zenawit Girmatsion; Ina Takac; Ralf P Brandes; Stefan Kissler; Inka Wiegratz; Sven Zumhagen; Birgit Stallmeyer; Stefan H Hohnloser; Thomas Klingenheben; Eric Schulze-Bahr; Stanley Nattel; Joachim R Ehrlich Journal: Eur Heart J Date: 2015-08-12 Impact factor: 29.983
Authors: Ilan Goldenberg; Samuel Horr; Arthur J Moss; Coeli M Lopes; Alon Barsheshet; Scott McNitt; Wojciech Zareba; Mark L Andrews; Jennifer L Robinson; Emanuela H Locati; Michael J Ackerman; Jesaia Benhorin; Elizabeth S Kaufman; Carlo Napolitano; Pyotr G Platonov; Silvia G Priori; Ming Qi; Peter J Schwartz; Wataru Shimizu; Jeffrey A Towbin; G Michael Vincent; Arthur A M Wilde; Li Zhang Journal: J Am Coll Cardiol Date: 2011-01-04 Impact factor: 24.094
Authors: Tengxian Liu; Barry S Brown; Ying Wu; Charles Antzelevitch; Peter R Kowey; Gan-Xin Yan Journal: Heart Rhythm Date: 2006-04-22 Impact factor: 6.343
Authors: Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett Journal: Expert Opin Drug Saf Date: 2014-12-10 Impact factor: 4.250